SCHEMBL1420152

SCHEMBL1420152

NC(=O)c1cccc(NC(=O)c2cc(N3CCC(N4CCCC4)CC3)cc(C(F)(F)F)c2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
RHOC P08134 1/20 0.47
RHOA P61586 1/20 0.47
PTGS1 P23219 2/20 0.47
NPY2R P49146 1/20 0.47
ALDH1A1 P00352 2/20 0.47
TP53 P04637 1/20 0.47
BRAF P15056 5/20 0.46
RAF1 P04049 4/20 0.46
CSF1R P07333 1/20 0.46
NTRK1 P04629 1/20 0.46
NTRK2 Q16620 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
ABL1 P00519 1/20 0.44
BCR P11274 1/20 0.44
PARP1 P09874 1/20 0.44
PARP15 Q460N3 1/20 0.44
PARP10 Q53GL7 1/20 0.44
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1420819 0.91 NPY2R (0.53) L3MBTL3L3MBTL1PTGS1NPY2RALDH1A1
SCHEMBL1420450 0.90 NPY2R (0.54) PTGS1NPY2RBRAFRAF1CSF1R
SCHEMBL1420117 0.89 LMNA (0.49) L3MBTL3L3MBTL1NPY2RTP53BRAF
SCHEMBL1420605 0.89 NPY2R (0.51) L3MBTL3L3MBTL1RHOCRHOANPY2R
SCHEMBL1420411 0.88 NPY2R (0.52) L3MBTL3L3MBTL1RHOCRHOANPY2R
SCHEMBL1420041 0.86 RHOA (0.53) L3MBTL3L3MBTL1RHOANPY2RBRAF
SCHEMBL1961348 0.86 DDR1 (0.48) NPY2RBRAFRAF1CSF1RNTRK1
SCHEMBL1420533 0.86 TRPV4 (0.57) L3MBTL3L3MBTL1NPY2RALDH1A1TP53
SCHEMBL1420252 0.86 CSF1R (0.47) L3MBTL3L3MBTL1NPY2RBRAFRAF1
SCHEMBL1961881 0.86 CSF1R (0.47) L3MBTL3L3MBTL1NPY2RBRAFRAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2011524365-A 2011-09-01 JP claimed
US-20110144107-A1 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA IRM LLC (BM) 2011-06-16 US claimed
EP-2297097-A2 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA IRM LLC (BM) 2011-03-23 EP claimed
WO-2009152356-A2 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA IRM LLC (BM) 2009-12-17 WO claimed
US-20110144107-A1 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA IRM LLC (BM) 2011-06-16 US disclosed
US-20110144107-A1 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA IRM LLC (BM) 2011-06-16 US disclosed
EP-2297097-A2 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA IRM LLC (BM) 2011-03-23 EP disclosed
WO-2009152356-A2 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA IRM LLC (BM) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144107-A1 COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA G6PD, DHFR, SGMS1 L3MBTL3 3831/4885L3MBTL1 3493/4885RHOC 595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.